Igenica Garners $33,000,000 Series C Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=218ffdfd-975b-4337-8cd2-87511125dc70&Preview=1 -
Date
6/12/2012 -
Company Name
Igenica -
Mailing Address
863 Mitten Road Burlingame, CA 94010 -
Company Description
Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer. -
Website
http://www.igenica.com -
Transaction Type
Venture Equity -
Transaction Amount
$33,000,000 -
Transaction Round
Series C -
Proceeds Purposes
Proceeds from the financing will be used to advance the company’s monoclonal antibody pipeline toward clinical trials. These funds will also be used to apply Igenica’s unique discovery approach, consisting of the sTAg target discovery platform and the iTAb antibody discovery platform, toward the discovery of new monoclonal antibodies against a broad range of drug targets that have not been previously investigated for the treatment of cancer. -
M&A Terms
-
Venture Investor
Third Rock Ventures -
Venture Investor
The Column Group -
Venture Investor
5AM Ventures -
Venture Investor
OrbiMed Advisors
